Acute Porphyria Drug Database

J05AH02 - Oseltamivir
Not porphyrinogenic
NP

Rationale
No CYP-interactions.
Chemical description
Antiviral neuramidinase inhibitor used perorally (up to 75 mg x 2 daily for 5 days) in symptomatic influenza in adults and children > 1 year, and as prevention after viral exposure in individuals > 13 years. About 90% of the absorbed dose is metabolzed by liver esterases, the carboxylated metabolite excreted in urine. CYPs are not involved in the biotransformation.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes J05A / J05AH or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙